Ono Pharmaceutical Co., Ltd.
Basic Information
- Stock Code
- 4528
- Industry
- Pharmaceuticals
- Category Detail
- Biotechnology & Pharmaceuticals
- Prefecture
- Osaka Prefecture
- Establishment Year
- June 1947
- Listing Year
- June 1962
- Official Website
- https://www.ono.co.jp/
- TSE Information
- TSE Information
- Yahoo! Finance
- Yahoo! Finance
- Other Companies
- Kyowa Kirin, Takeda Pharmaceutical, Astellas Pharma, Shionogi, Chugai Pharmaceutical, Eisai, Kissei Pharmaceutical, Santen Pharmaceutical, Daiichi Sankyo, Otsuka Holdings
Overview
Ono Pharmaceutical Co., Ltd. is a pharmaceutical company based in Osaka, founded in 1947. It features Opdivo, a pioneer in cancer immunotherapy, and boasts high expertise and profit margins as a semi-major player in the pharmaceutical industry.
Current Situation
For the fiscal year ending March 2025, Ono Pharmaceutical Co., Ltd. recorded consolidated net sales of approximately 4,869 billion yen, operating profit of approximately 597 billion yen, and net profit of approximately 500 billion yen, achieving rapid growth through the expansion of its prescription pharmaceutical business centered on oncology. Its flagship product Opdivo has gained widespread global adoption, enhancing competitiveness in both domestic and international markets. The company operates multiple research institutes and manufacturing sites, with an integrated system from drug discovery to manufacturing and sales. In recent years, it has strengthened quality assurance, drawing lessons from surging new drug development costs and past drug harm issues. It promotes business operations with sustainability in mind, executing management strategies to become a sustainable pharmaceutical company. Toward 2030, it has set strategic goals of advancing new drug development and accelerating global expansion. Going forward, it will focus on creating innovative pharmaceuticals centered on cancer treatments to contribute to solving social issues.
Trivia
Interesting Facts
- Opdivo is world-famous as a Japanese-originated cancer immunotherapy drug.
- An extremely historic company founded in 1717 as a drug wholesaler.
- Specializes in prescription pharmaceuticals and has withdrawn from OTC drugs.
- Opdivo research has deep ties to Nobel Prize winner Honjo.
- Operates three major research institutes domestically and abroad to drive R&D.
- Past OTC drug commercials featured famous celebrities.
- Possesses proprietary drug discovery platforms and has produced many new drugs.
- Boasts high profit margins among prescription pharmaceuticals.
- Expanding into health foods via subsidiaries.
- Manufacturing sites for prescription drugs meet high technological standards compliant with global benchmarks.
- Collaborates with numerous media through sponsorship activities.
- Past inappropriate sales led to drug harm litigation, but improvements have been made.
- Focuses on technological innovation in the pharma industry to maintain competitiveness.
- Actively engages in community contribution activities.
- Increasing overseas sales ratio through global expansion.
Hidden Connections
- Opdivo technology evolved from joint research with Nobel laureate Professor Honjo.
- Strengthens global business foundation with direct subsidiaries in Taiwan, Korea, U.S., and U.K.
- Subsidiary Ono Yakuhin Healthcare develops and sells health foods with function claims.
- Previously had a rare-in-industry OTC drug business from which it has withdrawn.
- In the 1960s, served as sole sponsor for TV programs to enhance corporate image.
- Maintains licensing partnerships and competitive relationships with multiple firms in the pharma industry.
- Manufacturing plants dispersed across Japan to balance risk dispersion and production efficiency.
- Established global presence as a Japanese originator in the high-value cancer immunotherapy market.
Future Outlook
Growth Drivers
- Sustained growth in cancer immunotherapy market and new indication expansions
- Improved drug discovery efficiency using AI and digital technologies
- Expansion of business in global markets
- Creation of differentiated products through formulation innovations
- Acceleration of licensing partnerships with collaborators
- Expansion of demand for chronic disease pharmaceuticals amid aging society
- Entry into growing health foods market
- Enhanced corporate value through sustainability and environmental measures
- Strengthened applications in regenerative medicine and biotechnology
- Advancement in data-driven healthcare
- Market trust secured through regulatory compliance and safety enhancements
- Innovation promotion via diverse talent utilization
Strategic Goals
- Achieve over 50% of sales from global markets
- Complete multi-area rollout of key new drugs
- Improve R&D efficiency to 1.5x current levels
- Establish sustainable corporate management based on ESG metrics
- Surpass 100 billion yen in annual health foods sales
- Build drug discovery platform leveraging digital technologies
- Strengthen social contribution activities to improve medical access
- Foster diverse talent and create supportive work environments
- Establish complete supply chain traceability
- Expand into emerging markets and promote region-specific product development
Business Segments
New Drug Development Technology Services
- Overview
- Provides technology support services from drug discovery to formulation development, supporting innovation in the pharmaceutical industry.
- Competitiveness
- R&D capabilities strong in cancer immunotherapy
- Customers
-
- Domestic and Overseas Pharmaceutical Companies
- Biotechnology Companies
- Research Institutions
- Medical and Pharmaceutical Universities
- Products
-
- Drug Candidate Research
- Clinical Data Analysis
- Pharmaceutical Manufacturing Technology Support
- Formulation Development Services
Pharmaceutical Raw Materials and Contract Manufacturing
- Overview
- Meets diverse medical needs through high-quality raw material supply and contract manufacturing services.
- Competitiveness
- Strict quality control standards and comprehensive factory facilities
- Customers
-
- Domestic and Overseas Pharmaceutical Manufacturers
- Generic Drug Companies
- Health Food Manufacturers
- Products
-
- Pharmaceutical Raw Material Supply
- Injectable Drug Contract Manufacturing
- Formulation Technology Support
Overseas Market Expansion Support
- Overview
- Provides support for regulatory affairs and sales in overseas expansion, promoting global deployment.
- Competitiveness
- Extensive international network and regulatory expertise
- Customers
-
- Overseas Pharmaceutical Companies
- Local Agents
- Global Medical Institutions
- Products
-
- Regulatory Approval Support
- Sales Partnerships
- Multilingual Services
Clinical Trial Support Services
- Overview
- Provides comprehensive support from clinical trial planning and operations to regulatory compliance.
- Competitiveness
- Proven track record and credibility in clinical trials
- Customers
-
- Pharmaceutical Companies
- Medical Facilities
- Contract Research Organizations
- Products
-
- Clinical Trial Management
- Data Management
- Regulatory Compliance Support
Licensing and Partnership Business
- Overview
- Promotes business expansion and new ventures through licensing of in-house developed products and technologies.
- Competitiveness
- Innovative immunotherapy technology centered on Opdivo
- Customers
-
- Domestic and Overseas Pharmaceutical Companies
- Biotech Ventures
- Products
-
- Pharmaceutical License-Out
- Joint R&D
Formulation R&D
- Overview
- Specializes in formulation technology development for new drugs to enhance product competitiveness.
- Competitiveness
- Advanced formulation technology holdings
- Customers
-
- In-House
- Group Companies
- Products
-
- Solid Dosage Forms
- Injectables
- Transdermal Patches
Foods with Function Claims Development
- Overview
- Engages in planning, development, and market launch support for health foods.
- Competitiveness
- Functionality leveraging pharmaceutical development know-how
- Customers
-
- Subsidiaries
- Health Food Distributors
- Products
-
- DHA/EPA Supplements
- Sleep Improvement Products
Global Quality Assurance
- Overview
- Builds and operates quality assurance systems compliant with regulations in each country.
- Competitiveness
- High-quality assurance system compliant with international standards
- Customers
-
- In-House
- Overseas Subsidiaries
- Products
-
- Quality Management Systems
- Regulatory Compliance Programs
Pharmaceutical Plant Operations and Management Services
- Overview
- Supports high-quality pharmaceutical production through efficient and safe manufacturing environment maintenance.
- Competitiveness
- Advanced production technology and equipment investments
- Customers
-
- In-House Plants
- Group Companies
- Products
-
- Production Equipment Management
- Safety and Health Management
- Environmental Compliance
Pharmaceutical Information Services
- Overview
- Supports safe treatment through accurate provision of pharmaceutical information.
- Competitiveness
- Extensive product knowledge and specialized staff
- Customers
-
- Healthcare Professionals
- Patient Inquiries
- Products
-
- Product Information Provision
- Medication Guidance Support
Treatment Area Awareness Support
- Overview
- Aims to improve medical quality through awareness activities starting with cancer treatment.
- Competitiveness
- Specialized knowledge and network in medical fields
- Customers
-
- Medical Institutions
- Patient Groups
- Government Agencies
- Products
-
- Seminars
- Educational Materials
Pharmaceutical Logistics Management
- Overview
- Logistics management services ensuring safe delivery of high-quality pharmaceuticals.
- Competitiveness
- Strict temperature and quality control
- Customers
-
- Distributors
- Medical Institutions
- Products
-
- Temperature-Controlled Logistics
- Product Traceability
Competitive Advantage
Strengths
- Innovative R&D capabilities in cancer immunotherapy
- Extensive domestic and international sales networks
- High profit margins and stable financial base
- Reliability and brand strength in the pharmaceutical industry
- Diverse pharmaceutical portfolio
- Consistent development and manufacturing system across sites
- Robust quality management and audit systems
- Global regulatory compliance capabilities
- Proactive license-out strategy
- Advanced formulation technology and manufacturing facilities
- Partnerships and collaborations with industry leaders
- Emphasis on sustainable business operations
- Utilization of multifaceted R&D sites
- Abundant intellectual property holdings
- Marketing prowess to win competitions
Competitive Advantages
- Overwhelming superiority in the cancer immunotherapy market with Opdivo
- Vertically integrated business model from discovery to sales
- Advanced international regulatory know-how supporting multinational expansion
- Efficient resource allocation maximizing R&D expenses
- Strong sales channels and partnerships domestically and abroad
- Successful product differentiation dominating high-price markets
- Diversification into health foods market linked with subsidiaries
- Trust secured through advanced quality assurance systems
- Brand enhancement via high-profile sponsorship activities
- Exclusive rights management via global patent portfolio
- Multi-site research labs in Fukui, Tsukuba, Minase, etc.
- High technological prowess in formulation R&D and manufacturing
- Strong negotiating power with major pharma companies for licensing
- Established robust network of medical experts
- Risk mitigation through quality control and drug harm response experience
Threats
- Risk of sharp increases in new drug development costs
- Profit pressure from strengthened international drug price regulations
- Competitor developments of Opdivo-like drugs
- Legal risks and litigation such as drug harm issues
- Product failure risks in global markets
- Geopolitical risks or natural disasters at manufacturing sites
- Competitive decline from delays in adapting to new technologies
- Generic penetration post-patent expiration
- Challenges in responding to rapid changes in global regulatory environment
- R&D capability decline from talent outflow
- Intensifying market competition in health foods business
- Uncertainty in overseas revenue due to exchange rate fluctuations
Innovations
2025: Opdivo Label Expansion Driving Market Growth
- Overview
- Obtained approval for expanded indications to new cancer types, broadening treatment areas.
- Impact
- Contributes to sales growth and market share expansion
2024: AI Utilization for Drug Discovery Process Efficiency
- Overview
- Introduced AI-based candidate compound screening technology to shorten development timelines.
- Impact
- Reduces R&D time by 20%
2023: Initiation of Clinical Trials for Next-Generation Immunotherapy Formulations
- Overview
- Launching Phase 2 trials for novel immune checkpoint inhibitors domestically and internationally.
- Impact
- Expected to strengthen future product lineup
2022: Nanoparticle Delivery Technology Development in Formulation
- Overview
- Developed nanoparticle-applied formulations to improve drug delivery efficiency.
- Impact
- Achieves reduced side effects and enhanced efficacy
2021: Introduction of Low-Environmental-Impact Production Processes
- Overview
- Promoting waste reduction and energy efficiency in manufacturing processes.
- Impact
- Successfully reduced CO2 emissions by 15%
Sustainability
- Continuous improvement of environmentally friendly manufacturing processes
- Promotion of diversity and employee engagement within the company
- Expansion of regional medical support and health education programs
- Introduction of energy-saving equipment and greenhouse gas reduction
- Thorough ethical procurement in the supply chain
- Implementation of employee health management programs
- Improvement of waste recycling rates
- Social contribution activities to improve medical access
- Strengthened collaboration with local communities
- Formulation and execution of sustainable procurement standards
- Establishment of transparent information disclosure systems
- Enhancement of corporate governance and compliance